{"prompt": "['Results in a change in study treatment (e.g., dosage modification, treatment interruption,', 'or treatment discontinuation)', 'Results in a medical intervention (e.g., potassium supplementation for hypokalaemia) or', 'a change in concomitant therapy', \"Is clinically significant in the investigator's judgment\", \"It is the investigator's responsibility to review all laboratory findings. Medical and scientific\", 'judgment should be exercised in deciding whether an isolated laboratory abnormality should', 'be classified as an AE.', 'If a clinically significant laboratory abnormality is a sign of a disease or syndrome', '(e.g., alkaline phosphatase and bilirubin 5 X ULN associated with cholestasis), only the', 'diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.', 'If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the', 'abnormality itself should be recorded on the Adverse Event eCRF, along with a descriptor', 'indicating whether the test result is above or below the normal range (e.g., \"elevated', 'potassium,\" as opposed to \"abnormal potassium\"). If the laboratory abnormality can be', 'characterized by a precise clinical term per standard definitions, the clinical term should be', 'recorded as the AE. For example, an elevated serum potassium level of 7.0 mEq/L should', 'be recorded as \"hyperkalaemia.\"', 'Observations of the same clinically significant laboratory abnormality from visit to visit should', 'only be recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for details on', 'recording persistent AEs).', '5.3.5.5', 'Abnormal Vital Sign Values', 'Not every vital sign abnormality qualifies as an AE. A vital sign result must be reported as', 'an AE if it meets any of the following criteria:', 'Is accompanied by clinical symptoms', 'Results in a change in study treatment (e.g., dosage modification, treatment interruption,', 'or treatment discontinuation)', 'Results in a medical intervention or a change in concomitant therapy', \"Is clinically significant in the investigator's judgment\", \"It is the investigator's responsibility to review all vital sign findings. Medical and scientific\", 'judgment should be exercised in deciding whether an isolated vital sign abnormality should', 'be classified as an AE.', 'If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high', 'blood pressure), only the diagnosis (i.e., hypertension) should be recorded on the Adverse', 'Event eCRF.', 'Observations of the same clinically significant vital sign abnormality from visit to visit should', 'only be recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for details on', 'recording persistent AEs).', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '73 / Protocol MO40628, Version 12']['5.3.5.6', 'Abnormal Liver Function Tests', 'The finding of an elevated ALT or AST (> 3 X baseline) in combination with either an', 'elevated total bilirubin (> 2 X ULN) or clinical jaundice in the absence of cholestasis or other', 'causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as', \"defined by Hy's Law). Therefore, investigators must report as an AE the occurrence of\", 'either of the following:', 'Treatment-emergent ALT or AST > 3 X baseline value in combination with total bilirubin', '> 2 X ULN (of which 35% is direct bilirubin)', 'Treatment-emergent ALT or AST > 3 X baseline value in combination with clinical', 'jaundice', 'The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal', 'laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.1) and', 'reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event),', 'either as an SAE or an AE of special interest (see Section 5.4.2).', '5.3.5.7', 'Deaths', 'For this protocol, mortality is an efficacy endpoint. Deaths that occur during the protocol-', 'specified adverse event reporting period (see Section 5.3.1) that are attributed by the', 'investigator solely to recurrence of breast cancer should be recorded on the Death Attributed', 'to Progressive Disease eCRF. All other deaths that occur during the adverse event', 'reporting period, regardless of relationship to study drug, must be recorded on the Adverse', 'Event eCRF and immediately reported to the Sponsor (see Section 5.4.2).', 'Death should be considered an outcome and not a distinct event. The event or condition', 'that caused or contributed to the fatal outcome should be recorded as the single medical', 'concept on the Adverse Event eCRF. Generally, only one such event should be reported. If', 'the cause of death is unknown and cannot be ascertained at the time of reporting,', '\"unexplained death\" should be recorded on the Adverse Event eCRF. If the cause of', 'death later becomes available (e.g., after autopsy), \"unexplained death\" should be replaced', 'by the established cause of death. The term \"sudden death\" should be used only for the', 'occurrence of an abrupt and unexpected death due to presumed cardiac causes in a patient', 'with or without pre-existing heart disease, within 1 hour after the onset of acute symptoms or,', 'in the case of an unwitnessed death, within 24 hours after the patient was last seen alive', 'and stable.', 'Deaths that occur after the adverse event reporting period should be reported as described', 'in Section 5.6.', '5.3.5.8', 'Pre-existing Medical Conditions', 'A pre-existing medical condition is one that is present at the screening visit for this study.', 'Such conditions should be recorded on the General Medical History and Baseline Conditions', 'eCRF.', 'A pre-existing medical condition should be recorded as an AE only if the frequency, severity,', 'or character of the condition worsens during the study. When recording such events on', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '74 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}